News & Updates

Show Multimedia Only

SC dose escalation restores efficacy of infliximab in IBD patients

17 Feb 2025 by

Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.

SC dose escalation restores efficacy of infliximab in IBD patients

17 Feb 2025

NASH cirrhosis tied to better survival than other aetiologies

14 Feb 2025

Compared with other aetiologies of cirrhosis, nonalcoholic steatohepatitis (NASH)-related cirrhosis is associated with better overall survival at 3 years, according to a study.

NASH cirrhosis tied to better survival than other aetiologies

14 Feb 2025

Endoscopic therapy most effective in recurrent acute pancreatitis

13 Feb 2025

A recent study has observed the varying efficacy of endoscopic therapy in patients with symptomatic pancreatic divisum (PD), with the highest success rate seen in recurrent acute pancreatitis.

Endoscopic therapy most effective in recurrent acute pancreatitis

13 Feb 2025

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

For patients with resectable esophageal adenocarcinoma, survival outcomes appear to be better with perioperative chemotherapy with FLOT vs preoperative chemoradiotherapy, according to a phase III study.

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025 by

When treating patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the neoadjuvant setting, chemoradiotherapy with or without sintilimab results in significantly higher pathological complete response (pCR) rates compared with chemotherapy plus sintilimab, according to preliminary data from the phase III SCIENCE trial from China.

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

Patients with hepatocellular carcinoma (HCC) who are receiving treatment with the combination of atezolizumab plus bevacizumab may be at risk of variceal bleeding, particularly those with a low platelet count, portal vein invasion, history of gastrointestinal bleeding, and varices needing treatment, as shown in a retrospective study.

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

09 Feb 2025

Faecal microbiota transplantation (FMT) with standardized anaerobic cultivated human intestinal microbiome is safe but does not appear to be efficacious in patients with systemic sclerosis experiencing lower gastrointestinal (GI) tract symptoms, according to a phase II study.

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

09 Feb 2025

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025 by

Dual immunotherapy with checkpoint inhibitors nivolumab and ipilimumab works better to slow disease progression in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) when compared with single-agent nivolumab, as shown in the phase III CheckMate 8HW trial.

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025

Anti-inflammatory diet wards off CKD

08 Feb 2025

Individuals on a pro-inflammatory diet are at greater risk of developing chronic kidney disease (CKD), suggests a study, noting the importance of adopting an anti-inflammatory diet to prevent CKD.

Anti-inflammatory diet wards off CKD

08 Feb 2025

Pandemic babies have a 46 percent higher risk of atopic diseases

05 Feb 2025 by

The incidence of atopic diseases in infants born in Hong Kong has increased by 46 percent during the COVID-19 pandemic, potentially linked to altered neonatal microbiome diversity resulting from vigorous disinfection. SIM03 and SIM05, symbiotic formulae developed with the aid of artificial intelligence (AI), are shown to improve eczema severity and quality of life (QoL) in children and adults, respectively, by modulating gut microbiota.

Pandemic babies have a 46 percent higher risk of atopic diseases

05 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

SC dose escalation restores efficacy of infliximab in IBD patients

SC dose escalation restores efficacy of infliximab in IBD patients

NASH cirrhosis tied to better survival than other aetiologies

NASH cirrhosis tied to better survival than other aetiologies

Endoscopic therapy most effective in recurrent acute pancreatitis

Endoscopic therapy most effective in recurrent acute pancreatitis

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

FMT of no benefit in systemic sclerosis patients with lower GI tract involvement

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

Anti-inflammatory diet wards off CKD

Anti-inflammatory diet wards off CKD

Pandemic babies have a 46 percent higher risk of atopic diseases

Pandemic babies have a 46 percent higher risk of atopic diseases